Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Summary of Components of Marketable Securities

	As of December 31, 2021
	Amortized		Unrealized		Unrealized			Fair
	Cost		Gains		Losses			Value
U.S. government obligations	$	650	$	17	$	-		$	667
Corporate obligations		8,304		-		(192	)		8,112
	$	8,954	$	17	$	(192	)	$	8,779

	As of December 31, 2020
	Amortized		Unrealized		Unrealized			Fair
	Cost		Gains		Losses			Value
U.S. government obligations	$	1,021	$	-	$	(7	)	$	1,014
Corporate obligations		629		-		(4	)		625
	$	1,650	$	-	$	(11	)	$	1,639

Schedule of Accounts Receivable Net

Accounts are written off as uncollectible at the time we determine that collections are unlikely. Accounts receivable, net is comprised of the following (in thousands):

	December 31, 2021			December 31, 2020
Trade accounts receivable	$	18,520		$	1,975
Unbilled accounts receivable		23,089			1,215
		41,609			3,190
Less allowances		(3,901	)		(35	)
Total accounts receivable	$	37,708		$	3,155

Schedule of Components of Inventory

At December 31, 2021 and 2020, the components of inventory are as follows (in thousands): 

	December 31,			December 31,
	2021			2020
Diagnostic services testing material	$	2,989		$	1,028
Raw materials		1,514			1,550
Work in process		260			440
Finished goods		272			188
Inventory	$	5,035		$	3,206
Inventory valuation reserve	$	(435	)	$	(167	)
Inventory, net	$	4,600		$	3,039

Schedule of Fair Value of Financial Instruments

	As of December 31, 2021
	Level 1		Level 2		Level 3		Total
U.S. government obligations	$	-	$	667	$	-	$	667
Corporate obligations		-		8,112		-		8,112
Marketable equity securities		76		-		-		76
	$	76	$	8,779	$	-	$	8,855

	As of December 31, 2020
	Level 1		Level 2		Level 3		Total
Marketable debt securities
U.S. government obligations	$	-	$	1,014	$	-	$	1,014
Corporate obligations		-		625		-		625
	$	-	$	1,639	$	-	$	1,639

Schedule of Deferred Revenue

The following table disaggregates our deferred revenue by recognition period (in thousands):

	As of December 31, 2021		As of December 31, 2020
Recognition Period
0-12 Months	$	2,034	$	169
13-24 Months		530		84
Over 24 Months		375		78
Total	$	2,939	$	331

Schedule of Disaggregation by Revenue

The following table disaggregates the Company’s revenue by revenue source for Fiscal 2021 and 2020 (in thousands):

	For the years ended
Revenue by Customer Type	December 31, 2021		December 31, 2020
Diagnostic services	$	68,559	$	1,277
Contract manufacturing		5,786		12,252
Retail and others		2,454		985
Genomic products and services		2,243		-
Total revenue, net	$	79,042	$	14,514